A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates - Trial NCT06398808
Access comprehensive clinical trial information for NCT06398808 through Pure Global AI's free database. This Phase 2 trial is sponsored by Zydus Lifesciences Limited and is currently Recruiting. The study focuses on Ulcerative Colitis. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zydus Lifesciences Limited
Timeline & Enrollment
Phase 2
Apr 08, 2024
Oct 30, 2024
Primary Outcome
To assess the efficacy of ZYIL1 for induction of clinical remission
Summary
The purpose of this study is to evaluate efficacy and safety of ZYIL1 oral capsule twice a
 day for 12 weeks for treatment of mild to moderate active ulcerative colitis resistant or
 intolerant to oral aminosalicylates.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06398808
Non-Device Trial